Objective: Phenobarbital is frequently used in pediatric patients for treatment and prophylaxis of seizures. Pharmacokinetic data for this patient population is lacking and would assist in dosing decisions. Methods: A retrospective population pharmacokinetic analysis was designed for all pediatric patients <19 years of age initiated on phenobarbital at our institution from January 2011 to June 2017. Patients were included if they were initiated on intravenous or enteral phenobarbital for treatment or prophylaxis of seizures and had a serum phenobarbital concentration monitored while an inpatient. Data collection included the following: age, weight, height, gestational age, core body temperature, serum creatinine, blood urea nitrogen, aspartase aminotransferase, alanine aminotransferase, urine output over the prior 12 hours, phenobarbital doses and serum concentrations, and potential drug-drug interactions. Descriptive statistical methods were used to summarize the data. Pharmacokinetic analysis was performed with NONMEM and simulation was performed for doses of 10, 20, 30, and 40 mg kg À1 dose À1 , iv, followed by enteral doses of 3, 4, 5, and
| BACKGROUND
Phenobarbital is a barbiturate antiepileptic drug that is used widely in the treatment and prophylaxis of seizures in neonatal and pediatric patients. 1 In general, phenobarbital is used for generalized and partial convulsive seizures and has widespread use in the neonatal population. [1] [2] [3] Data for phenobarbital have been published in the neonatal population, but, despite the long history and large amount of use in the pediatric population, the pharmacokinetics of phenobarbital have not been quantified across the pediatric age spectrum. [3] [4] [5] [6] Neonatal patients can have significant changes in organ function secondary to growth and maturation, which can affect the pharmacokinetic profile of medications. 7, 8 In addition, medical interventions, such as wholebody hypothermia in neonates with hypoxic ischemic encephalopathy, may also alter the disposition of medications in pediatric patients. 9 Bioavailability of phenobarbital has been documented at~90%, but has been shown to be much less in neonates. 10, 11 The half-life of phenobarbital is long; therefore, accurate empiric dosing is necessary to obtain target concentrations in a timely fashion. 12 Overall, characterization of phenobarbital pharmacokinetics in this population can contribute to improved dosing and potentially improved outcomes. Therefore, we performed a population pharmacokinetic analysis of phenobarbital in pediatric patients (<19 years of age) who were receiving therapy for seizure treatment or prophylaxis.
| METHODS
A retrospective descriptive population pharmacokinetic study was designed and the study was approved by the Baylor College of Medicine and Affiliated Institutions Institutional Review Board. Patients were identified by querying of the hospital electronic medical record system for patients who received phenobarbital as inpatients from January 1, 2011 to June 30, 2017 . Patients were included in the study if they were <19 years of age, initiated on intravenous or oral phenobarbital therapy for treatment or prophylaxis of seizures at our institution, and had one or more serum phenobarbital concentrations sampled. Patients were excluded if they were undergoing any type of renal replacement therapy, mechanical circulatory support, or were taking phenobarbital prior to admission. Patients had data collected for their inpatient stay. Phenobarbital is dosed, per institutional guidelines as follows: loading doses of [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Data collection included the following: patient age in years, gestational age, weight (WT), height, serum creatinine (SCR), blood urea nitrogen (BUN), core body temperature (Fahrenheit), aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum albumin (ALB), urine output over the previous 12 hours (UO), phenobarbital dose, and phenobarbital serum concentrations. In addition, potential drug-drug interactions were identified and collected as part of the dataset.
Phenobarbital serum concentrations were collected in either a 1 9 0.6 mL Green Lithium Heparin (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) or 1 9 1 mL Red No Additive Vacutainer (Becton, Dickinson and Company). The phenobarbital serum concentrations were analyzed by chemiluminescent micro particle immunoassay (VITROS, Ortho Clinical Diagnostics; Raritan, NJ, USA) with an analytical measurement range of 5-80 mg/L and a precision of <5%.
| Descriptive analysis
The patient population was described, using percentages, mean, standard deviation, median, and range, for normally and nonnormally distributed data, as appropriate. Postmenstrual age (PMA) was calculated in weeks. For patients older than 1 year of age with no documented gestational age, 40 weeks of gestation was used. Fat-free mass (FFM) was calculated for all patients. 13 Graphical representation of the initial data was also utilized to evaluate the data. Statistical analyses were performed using Stata IC v.12 (StataCorp, College Station, TX, USA), and Excel 2013 (Microsoft Corp, Redmond, WA, USA).
| Pharmacokinetic analysis
Population pharmacokinetic analysis was performed with NONMEM v.7.3 (Icon, PLC; Dublin, Ireland) and PDxPop 5.2 (Icon) using first-order conditional estimation with interaction (FOCE-I). The base model was developed through analysis of prior literature and visually evaluation of graphs of serum concentrations of phenobarbital after dosing ( Figure S1 ). In addition to clearance (CL) and
Key Points
• Postmenstrual age should be used to guide phenobarbital dosing in children <2 years of age
• Several drug-drug interactions were identified that alter phenobarbital pharmacokinetics
• Phenobarbital pharmacokinetics were not affected by body temperature volume of distribution (Vd), absorption rate constant (Ka) and bioavailability (F) were included in the base model. Potentially significant covariates were plotted against pharmacokinetic parameters to initially evaluate suitability for inclusion in the model. Power, linear, and linear proportional models were evaluated with continuous covariates, and categorical covariates were modeled exponentially. The change in g plots upon addition of a covariate was evaluated. Covariates were included in the base model if a reduction in the objective function value (OFV) was >3.84, signifying statistical significance (P < .05) for 1 degree of freedom. After significant covariates were identified, a full model, containing all significant covariates, was developed. Individual covariates were then removed from the model, from least change in OFV to the greatest change in OFV, and were then considered to be retained in the model if the OFV increased by >10.83, which has a significance level of P < .001.
To evaluate model goodness of fit and detect bias, scatter plots of dependent variables (DV) vs individual predicted (IPRE) and population predicted (PRED) phenobarbital serum concentrations were developed, along with IPRE vs conditional weighted residuals (CWRES) and CWRES vs time after dose. Prediction corrected visual predictive check was also developed. Bootstrap simulations were performed (n = 1000) on the final model with calculation of 95% confidence intervals around point estimates.
A simulation was performed using NONMEM with the final population model (and the measures of variability) developed from the analysis. A "virtual" patient for each age group was developed and covariate values representative for the patient age group were selected. This "virtual" patient was simulated with the final population pharmacokinetic model 10 000 times, and results of serum concentrations were summarized. Bolus doses of 10, 20, 30, and 40 mg kg À1 dose À1 were evaluated in the first simulations to determine an optimal intravenous phenobarbital loading dose that would achieve a serum concentration of 20-40 mg/L at 2 hours postdose. Using the optimal loading dose, simulation was performed for oral phenobarbital dosing to maintain a trough concentration of 20-40 mg/L after 7 days of therapy.
| RESULTS

| Demographics
A total of 355 patients met inclusion criteria and demographic data were summarized (Table 1) . Drug-drug interactions were also evaluated ( . Intravenous phenobarbital was administered at a rate of 30 mg/min per institutional guidelines. Two concentrations were below the range of the assay, and these were treated as zero. The mean serum concentration was 41.1 AE 23.9 mg/L, which was drawn at a median of 6.5 (IQR 2.9, 11.1) hours after a dose. The only covariate with missing values was ALB, and these missing values were in <10% of the population. These values were imputed with the median value of ALB from the dataset.
| Pharmacokinetic modeling
A one-compartment proportional error model using firstorder conditional estimation with interaction (FOCE-I) was chosen as the base model with absorption rate constant and bioavailability (ADVAN 2, TRANS 2). The model fit best when interindividual variability (IIV) was placed only on CL and Vd and removed from bioavailability (F) and absorption rate constant (Ka). WT and FFM, with allometric scaling components of 1 (Vd) and 0.75 (WT and FFM), were added to the model, and FFM had the greatest decrease in OFV by À799.92. The model using FFM was then used as the base model for subsequent covariate modeling (Table S1 ). Drug-drug interactions that were significant for a reduction in OFV included oxcarbazepine, lansoprazole, zonisamide, midazolam, phenytoin (enteral), rifampin, pantoprazole, and felbamate when applied to CL, and valproate when applied to Vd ( Table 2 ). The CL of phenobarbital was noted to be decreased in the youngest of patients, and a sigmoidal model using PMA was evaluated to describe the increase in CL over PMA ( Figure 1) ; this resulted in a significant reduction in OFV. Patient CL values were~50% at 41 weeks PMA, per visual inspection of the plots, reaching full value at~100 weeks PMA, or, close to 2 years of age. Multiple values for PMA were evaluated in the sigmoidal model, and the use of 41 weeks resulted in the lowest OFV and was subsequently fixed at that value. Estimating PMA resulted in a higher OFV than the model that used 41 weeks.
Age in years (AGEYRS) had a slight effect on Vd, with decreasing values as age increases, and resulted in significant changes in the OFV when removed from the model. Temperature, when used as a continuous covariate, did not have a significant association with CL. No single covariate resulted in a >20% decrease in IIV when added to the base model. In the model with FFM (base model prior to covariate modeling), g-shrinkage values for CL and Vd were 40.6% and 11.1%, respectively. Overall, these values did not change in final model, with g-shrinkage values for CL and Vd of 42.7% and 9.1%.
The final model then included SCR, PMA, pantoprazole, midazolam, and phenytoin (enteral) on CL, and AGEYRS on Vd (Table 3) . Diagnostic plots demonstrated good fit of the model (Figures S2-S6 ) Bootstrap analysis of 1000 runs was performed and 100% of runs were successfully minimized (Table S2) .
A virtual patient was developed, one for each age group for (neonatal, infant, child, adolescent) ( Table 4 ). Each of these virtual patients had 10 000 simulations performed with the developed model for various dosing strategies. Initially, doses of 10, 20, 30, and 40 mg kg À1 dose À1 were evaluated in the first simulations to determine an optimal intravenous phenobarbital loading dose that would achieve a serum concentration of 20-40 mg/L at 2 hours post-dose. Using the optimal loading dose, simulation was performed for oral phenobarbital dosing to maintain a trough concentration of 20-40 mg/L after 7 days of therapy (Table 4) . 
| DISCUSSION
T A B L E 2 Drug-drug interactions evaluated
F I G U R E 1 Clearance of phenobarbital vs postmenstrual age.
Clearance follows a sigmoidal pattern with increasing postmenstrual age Volume of distribution was noted to decrease with increasing age. The lack of effect of body temperature on phenobarbital pharmacokinetics was supported by prior publications, which investigated cooling in neonates with hypoxic ischemic encephalopathy. 14 Renal clearance of phenobarbital has been reported at~21% of the total dose and we verified the influence of SCR on CL of phenobarbital. 15 We were able to characterize the clearance of phenobarbital over the neonatal and infant periods by PMA using a sigmoidal model, suggesting maturation of enzymes extending into the postnatal period. 16, 17 Prior investigations into the effect of cooling on phenobarbital CL had demonstrated a significant effect using postnatal age with a sigmoidal model, which would also suggest enzyme maturation with age. 14 Phenobarbital is metabolized extensively by the cytochrome P450 (CYP) system, and the maturation of this enzyme family during the neonatal period has been well described in the literature. 7, 8, 18 The 2C19 subunit of the CYP enzyme is responsible for phenobarbital metabolism, and this subunit matures significantly over the first 6 months of life. 19 However, investigations into neonatal patients who expressed variants of the 2C19 subunit of the CYP system in neonates did not elucidate any differences in phenobarbital CL. 20 We did not have any information regarding genetic polymorphisms in this dataset and were therefore unable to evaluate any pharmacogenetics differences in our patient population and thus can only speculate that the changes in CL we have demonstrated are directly associated with enzyme maturation. Based on the simulation performed, a neonate of 36 weeks gestation at 1 month of age would require a lower total daily enteral dose of phenobarbital than older patients would, presumably due to enzyme maturation. However, there are many variables, such as enzyme polymorphisms and bioavailability, that could influence dosing in this patient group. We recommend that PMA be considered when dosing phenobarbital in patients younger than 2 years of age to account for the changes in CL over the neonatal and infant age period. Bioavailability was determined to be~90%, which has been reported as bioavailability in adults, but was significantly higher than what has been previously reported in neonates. 5, 10, 21 The bioavailability of phenobarbital in the youngest patients has been estimated to be at <50% and oral doses often need to be increased when switching patients from intravenous to oral therapy in neonates. 22 Anecdotally we have noticed the need for increasing phenobarbital doses when switching from intravenous to oral therapy in patients younger than 14 days postnatal age. The maturation of gastric acid secretion in the neonate is thought to have a role in the decreased bioavailability of phenobarbital in this age group.
23-25
The differences in bioavailability that were noted in this analysis, as compared to other reports, may be due to the fact that the median patient age was~3 months and gestational age was 39 weeks. Marsot et al published a phenobarbital bioavailability of 48.9% with patients that were a mean of 29 days of age and a gestational age of 37 weeks. 22 It has been suggested that doses need to be increased when oral administration is used, by as much as 2-fold, in the youngest of patients to achieve therapeutic concentrations. 22 We suggest that therapeutic drug monitoring be used to monitor these patients, due to the variability in bioavailability, in order to attain optimal serum concentrations. Drug-drug interactions were variables identified to significantly influence phenobarbital pharmacokinetics in pediatric patients and are unique to this analysis. The drugdrug interactions identified in this analysis are significant for their potential concomitant use during phenobarbital therapy. However, we also recognize that the population receiving some of the interacting medications was small (<10%). The small sample of interacting medication should be considered when interpreting the clinical outcomes potentially associated with these outcomes. The interaction between phenobarbital and phenytoin (enteral) is controversial, with some reports identifying an interaction that increases phenobarbital serum concentrations, others identifying increased phenytoin concentrations, and others with no interaction at all. [26] [27] [28] [29] An investigation by Encinas et al demonstrated that phenobarbital serum concentrations were initially elevated with concomitant phenytoin administration, but normalized over time. 28 The data presented 31 When patients are concomitantly prescribed interacting medications, serum concentration monitoring of phenobarbital is warranted due to the alterations in phenobarbital CL that have been identified. Retrospective reviews are subject to limitations associated with accuracy of medical charting, and this review is no exception. The recommendations we have provided in regard to loading doses and maintenance doses are based on the ability to attain therapeutic serum concentrations. These recommendations should be tempered with patient clinical scenario, goal outcomes, and the potential for adverse events with higher doses of phenobarbital, such as excessive sedation or hypotension. FFM was chosen due to the significance in reduction of OFV, but also as a better marker of end-organ function as opposed to WT. This does not preclude the careful monitoring of pediatric patients with excessive adipose tissue, as phenobarbital is highly lipophilic. We did not include patients who required renal replacement therapy or mechanical circulatory support, and these patients will likely require more intensive monitoring and dose adjustment. We have assumed a goal concentration of 20-40 mg/L when evaluating dosing regimens through simulation. This range may or may not be applicable to each patient depending on overall goals of therapy, and these dosing recommendations should inform a holistic approach to patient care.
| CONCLUSIONS
Phenobarbital dosing should incorporate fat-free mass, postmenstrual age, serum creatinine, and age in years. An intravenous dose of 30 mg/kg once followed by 4-6 mg kg À1 d À1 divided twice daily resulted in therapeutic serum concentrations at 7 days. Drug-drug interactions of midazolam, phenytoin, and pantoprazole significantly affected phenobarbital.
T A B L E 4 Attainment of therapeutic concentrations from dosing simulation
Age group (n = 10 000) 
